Startseite Galectin-3 expression in colorectal cancer and its correlation with clinical pathological characteristics and prognosis
Artikel Open Access

Galectin-3 expression in colorectal cancer and its correlation with clinical pathological characteristics and prognosis

  • Liu Tao , Li Jin , Li Dechun EMAIL logo , Yang Hongqiang , Kou Changhua und Lei Guijun
Veröffentlicht/Copyright: 13. Juli 2017

Abstract

Objective

To explore the expression levels of galectin-3 in colorectal cancer and the association between galectin-3 and its clinical pathological parameters, as well as the prognosis of colorectal cancer patients.

Methods

An immunohistochemistry assay was used to test the expression levels of galectin-3 in cancer tissues of 61 colorectal cancer cases and in normal intestinal tissues adjacent to the cancer tissues of 23 cases. The associations between protein expression levels of galectin-3 and the clinicopathological features, such as age, sex, pathology type, lymphatic metastasis, and prognosis were also analyzed.

Results

The positive rate of galectin-3 in cancer tissues was significantly higher than that of cancer-adjacent tissues: 62.5% (38/61) versus 13.0% (3/23) (P<0.05), respectively. Correlation was found between the protein expression of galectin-3 and the tumor size (P<0.05), as well as between the tumor differentiation (P<0.05) and Duke staging (P<0.05). The median progression-free survival times of patients with galectin-3 positive and negative expression were 19.2 and 35.1 months, respectively, with significant statistical difference (P<0.05).

Conclusion

Galectin-3 expression was correlated with the genesis and development of colorectal cancer and which could be used a biological marker for the prognosis of colorectal cancer patients.

1 Introduction

With the advances in molecular biology, colorectal cancer is now considered by most investigators to be a pathological process involving multiple genes and steps [1,2]. Activation of oncogenes and inactivation of anti-oncogenes play important roles during this process [2-4]. Galectin-3 belongs to the galectin family, which is involved in multiple biological behaviors, such as cell proliferation, apoptosis, and adhesion via combination with different proteins [5]. Elevated expression of galectin-3 was observed in tissues of multiple solid malignant tumors, whereas low or no expression was observed in normal tissues [6-8]. In the present study, an immunohistochemical assay was performed to measure the expression levels of galectin-3 in colorectal cancer tissues, as well as in tissues adjacent to the cancerous ones in order to explore the correlation between galectin-3 expression and clinical pathological features, as well as prognosis.

2 Material and methods

2.1 Clinical samples

Colorectal cancer patients who were surgically treated in our general surgery department from March 2012 to January 2015 were selected as study objects. The inclusion criteria was described as follows: colorectal cancer was validated by pathology, clinical medical data were complete for the patients with complete follow-up data, and histopathological sample testing was approved in written form by the patient or his/her family. However, patients who met the following criteria were excluded from the study: unclear histopathological diagnosis, neoadjuvant chemoradiotherapy, incomplete follow-up data, and complicated history of other malignant tumors. Cancer tissue samples from all the 61 subjects and adjacent tissue samples from 23 patients were included in the study. The average age of the 61 patients was 65.1±15.65 years. For the included 61 patients, there were 33 male and 28 female with 27 colon cancer cases and 34 rectal cancer cases. 36 patients were diagnosed at A/B staging and 25 patients at C/D staging according to the Duke staging system.

Ethical approval

The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.

2.2 Instruments and reagents

A paraffin slicing machine (Leica, Germany), microscope (Olympus, Japan), electrothermostat (Shezhen Ruitai Co., Ltd., China), microwave oven, conventional centrifuge (Beijing BaiYangMedical Devices Co., Ltd.), purified water system (Millipore, Germany), mouse anti-human galectin-3 monoclonal antibody (Santa Cruz Biotechnology, USA), immunohistochemical staining kit SP-9000 (Beijing Zhongshan Biotechnology Co., Ltd., China), and DAB Displaying Kit (Beijing Zhongshan Biotechnology Co., Ltd., China) were used in this study.

2.3 Immunohistochemical assay

Paraffin wax samples of cancer tissues and adjacent tissues were incised into paraffin sections with a diameter of 4 μm. Histological sections were first soaked into dimethylbenzene for 10min, followed by dehydrated alcohol for 5 min, and then in succession in the following alcohol solutions for 5 min each for dewaxing with 95%, 80%, and 79% alcohol. These slices were soaked in 3% H2O2 (30% H2O2:methanol=l:9) and then incubated in the dark for 15min. To inactivate endogenous peroxidase, 0.01% mol/L sodium citrate was added to the sections. The sections were then placed in a water bath heated at 95°C for 15 min. A drop of 100μl of normal serum containing 10% diluted TBST was added to the tissues. These tissues were incubated over night at 4°C. A 1:100 secondary antibody was added with HRP marking for incubation under room temperature for 1 h. Coloration with the coloring reagent was performed by washing the samples with dH2O twice for 5 min to 10 min. Afterward, the sections were sealed. The sections were then dried prior to observation under a microscope. The samples were evaluated by cell staining with the following scores: brown, 3 points; pale brown,2 points; light brown,1 point; and no coloration, 0 points. The quantity of stained cells was evaluated with the following scores: quantity of stained cells in one visual field of>75%, 4 points; 51% to 75%, 3points; 11% to 50%, 2 points; <10%, 1 point; and negative, 0 points. The final result is achieved by multiplying the scores from the two categories: 0 to 3 points, negative expression (−); 4 to 6 points, weakly positive expression (+); 7 to 9 points, fairly strong positive expression (++); and 9 to 12 points, strong positive expression (+ + +).

2.4 Follow up

Periodic follow up by phone or outpatient service was performed after therapy. Hospitalized treatment was performed for patients requiring adjuvant chemotherapy in accordance with the NCCN guideline. The disease progression and time of death of patients (in case of mortality) were recorded.

2.5 Statistical analysis

For statistical analysis, x ± s was used to represent the measurement data for each patient, whereas t-test was used for group comparison. The ratio was used to represent the enumeration data and compared by Chi-square test. The survival data was represent by median. The log-rank method of Kaplan–Meier survival curve was used to compared the survival difference of the two groups. Statistical significance was determined for bilateral P<0.05. SPSS16.0 software was used for all statistical analyses in this study.

3 Results

3.1 Expression of galectin-3

In this study, galectin-3 was primarily expressed in the cytoplasm and cell membrane with yellow-brown granules. The positive rates of galectin-3 in cancer tissues and adjacent normal tissues were 62.5% (38/61) and 13.0% (3/23), respectively. Galectin-3 positive expression rate was significantly higher in cancer tissues than that in adjacent normal tissues (P<0.05), Figure 1.

Figure 1 Galectin-3 expression in colorectal cancer tissue and normal intestinal tissues by immunohistochemistry(A: galectin-3 negative expression in normal intestinal tissues, × 200; B: galectin-3 positive expression in normal intestinal tissues, × 200; C: galectin-3 negative expression in colorectal cancer tissues, × 400; D: galectin-3 positive expression in colorectal cancer tissues, × 400)
Figure 1

Galectin-3 expression in colorectal cancer tissue and normal intestinal tissues by immunohistochemistry

(A: galectin-3 negative expression in normal intestinal tissues, × 200; B: galectin-3 positive expression in normal intestinal tissues, × 200; C: galectin-3 negative expression in colorectal cancer tissues, × 400; D: galectin-3 positive expression in colorectal cancer tissues, × 400)

3.2 Correlation between Galectin-3 expression and patients clinicopathological features

Correlation was found between the protein expression of galectin-3 and the tumor size (P<0.05), tumor differentiation (P<0.05) and Duke staging (P<0.05). But it was not correlated with patient’s gender (P>0.05), age (P>0.05), tumor location (P>0.05), and gross type (P>0.05), Table 1.

Table 1

The association between Galectin-3 protein expression and clinical pathological characteristics

Characteristicsn=61Galectin-3expressionChi-squcreP
Positive (n=38)Negative (n=23)
Age (vears)0.00.91
≤5017116
>50442717
Gender0.140.71
Male332211
Female281612
Tumor location0.390.53
Colon27189
Rectal342014
Pathology grading6.990.01
Well-differentiated1349
Poor-differentiated483414
Tumor diameter (cm)5.190.02
>530237
≤5311516
Duke stage5.650.02
 A/B361818
C/D25205
Tumor gross type1.080.58
Mass forming251510
Infiltrative271611
Ulcerative972

3.3 Galectin-3 expression and prognosis

The median progression-free survival time for patients with positive and negative galectin-3 expression were 19.2 and 35.1 months, respectively. The risk of disease progression for patients with positive galectin-3 expression was significantly higher than that for patients with negative galectin-3 expression (HR=2.10, 95%CI:1.05 to 4.17, P<0.05), Figure 2.

Figure 2 The disease survival curve comparison between galectin-3 positive and negative patients
Figure 2

The disease survival curve comparison between galectin-3 positive and negative patients

4 Discussion

In 2012, clinical epidemiology studies reported that about 140,000 patients were diagnosed with colorectal cancer in North America; up to 50,000 patients died from colorectal cancer in the same year [9]. No authoritative and accurate epidemiological data are available for colorectal cancer in China [10]. On the basis of the incidence of colorectal cancer from several provinces, this malignancy ranks behind the incidence of lung cancer, breast cancer, and gastric cancer [11-14]. The exact cause of colorectal cancer remains unclear. Most studies regarded colorectal cancer to be associated with a family history of tumors, adenoma of the colon, high-fat and high-protein diets, and limited amounts of exercise [15-17].

Recent studies showed that the inactivation of certain anti-oncogenes and the activation of oncogenes play important roles in the genesis and progression of colorectal cancer [18]. Relevant protein factors are particularly important in the activation of oncogenes or the significant increase in their expression levels. Galectin-3 is one of the members of galectin protein family. These proteins are involved in multiple biological behavior, such as cell proliferation, apoptosis, and adhesion. In humans, the galectin-3 gene is located at 14q21- 22 and is composed of 6 exons and 5 introns. Galectin-3 protein is produced in the nucleus and localized mainly in the cytoplasm at the cell surface and outside the cell, exerting multiple effects via interaction with corresponding ligands. Clinical studies demonstrated that galectin-3 is highly expressed in tissues of multiple solid tumors, including esophageal cancer, gastric cancer, lung cancer, and liver cancer. Moreover, galectin-3 expression is correlated with a patient’s prognosis [19-22]. Wan et al [23] employed an immunohistochemical method to test the expression level of galectin-3 in tissues of gastric cancer and determine its correlation with the pathological features and prognosis of patients. Studies showed that the positive expression rate of galectin-3 in tissues of gastric cancer is relatively high and correlated with invasive depth and lymphatic metastasis. Li et al [24] reported that galectin-3 expression is significantly higher in colorectal cancer tissues than that of normal intestinal tissue. These reports conclude that galectin-3 plays an important role in the genesis and progression of colorectal carcinoma.

In the present study, we found that the positive expression rate of galectin-3 in colorectal cancer tissues was 62.5% (38 / 61), whereas the positive expression rate of galectin-3 in normal tumor-adjacent intestinal epithelial tissues was 13.0% (3 / 23). The positive rate of cancer tissues was significantly higher than that of normal tumor-adjacent tissues. This finding is consistent with the report of Li et al [24], suggesting that galectin-3 may be involved in the genesis and progression of colon cancer. We also found that tumor size was relatively large with low differentiation extent and late clinical staging in patients with positive expression. These parameters are indicators of relatively poor prognosis. Analysis of the association between the expression level of galectin-3 and the survival rates indicated that the median progression-free survival time of patients with positive galectin-3 expression was significantly shorter than that of patients with negative expression. This result indicated that the positive expression of galectin-3 was associated with more malignant biological behavior of colorectal cancer and can be used as a predictor of poor prognosis for patients. The association between galectin-3 expression and clinical features, as well as the prognosis for patients, is evident, but the molecular mechanism on how galectin-3 controls genesis, progression, invasion, and metastasis of colorectal cancer remains unclear [25, 26]. Therefore, immunoblotting and co-immunoprecipitation assays should be further performed to explore the underlying molecular mechanisms controlling the malignant biological behavior of colorectal cancers.


Tel:+86- 0512-65223637
Liu Tao and Li Jin contributed equally to this work.
  1. Conflict of interest

    Conflict of interest statement: Authors state no conflict of interest

Reference

[1] Cherry LM. The genetic etiology of familial and nonfamilial colorectal cancer[J]. Proceedings (Baylor University. Medical Center), 2011,24(2):139-14110.1080/08998280.2011.11928702Suche in Google Scholar

[2] Wang LS, Kuo CT, Huang YW, et al. Gene-Diet Interactions on Colorectal Cancer Risk[J]. Curr Nutr Rep, 2012,1:132-14110.1007/s13668-012-0023-1Suche in Google Scholar

[3] Belkhiri A, El-Rifai W. 5-Methylcytosine hydroxylation-mediated LINE-1 hypomethylation: a novel mechanism of proto-oncogenes activation in colorectal cancer?[J]. Gut, 2014,63(4):538-53910.1136/gutjnl-2013-305176Suche in Google Scholar

[4] Hur K, Cejas P, Feliu J, et al. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis[J]. Gut, 2014,63(4):635-64610.1136/gutjnl-2012-304219Suche in Google Scholar

[5] Argueso P, Mauris J, Uchino Y. Galectin-3 as a regulator of the epithelial junction: Implications to wound repair and cancer[J]. Tissue Barriers, 2015,3(3):e102650510.1080/21688370.2015.1026505Suche in Google Scholar

[6] Sanjuán X, Fernández PL, Castells A, et al. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression[J]. Gastroenterology, 1997,113(6):1906-191510.1016/S0016-5085(97)70010-6Suche in Google Scholar

[7] Nakajima K, Heilbrun LK, Hogan V, et al. Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I[J]. Oncotarget, 201610.18632/oncotarget.12619Suche in Google Scholar PubMed PubMed Central

[8] Subhash VV, Ho B. Galectin 3 acts as an enhancer of survival responses in H. pylori-infected gastric cancer cells[J]. Cell Biol Toxicol, 2016,32(1):23-3510.1007/s10565-016-9315-3Suche in Google Scholar PubMed

[9] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015,65(1):5-2910.3322/caac.21254Suche in Google Scholar PubMed

[10] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-13210.3322/caac.21338Suche in Google Scholar PubMed

[11] Endo K, Kohnoe S, Tsujita E, et al. Galectin-3 expression is a potent prognostic marker in colorectal cancer[J]. Anticancer Res, 2005,25(4):3117-3121Suche in Google Scholar

[12] Chen W, Zheng R, Zeng H, et al. Epidemiology of lung cancer in China[J]. Thorac Cancer, 2015,6(2):209-21510.1111/1759-7714.12169Suche in Google Scholar PubMed PubMed Central

[13] Lin Y, Ueda J, Kikuchi S, et al. Comparative epidemiology of gastric cancer between Japan and China[J]. World J Gastroenterol, 2011,17(39):4421-442810.3748/wjg.v17.i39.4421Suche in Google Scholar PubMed PubMed Central

[14] Hao XS, Chen KS, Liu H. Analysis of Female Breast Cancer Descriptive Epidemiology in Tianjin, China[J]. Asian Pac J Cancer Prev, 2002,3(2):143-148Suche in Google Scholar

[15] Lynes K, Kazmi SA, Robery JD, et al. Public appreciation of lifestyle risk factors for colorectal cancer and awareness of bowel cancer screening: A cross-sectional study[J]. Int J Surg, 2016,36(Pt A):312-31810.1016/j.ijsu.2016.11.002Suche in Google Scholar PubMed

[16] Tuan J, Chen YX. Dietary and Lifestyle Factors Associated with Colorectal Cancer Risk and Interactions with Microbiota: Fiber, Red or Processed Meat and Alcoholic Drinks[J]. Gastrointest Tumors, 2016,3(1):17-2410.1159/000442831Suche in Google Scholar PubMed PubMed Central

[17] Jayasekara H, Reece JC, Buchanan DD, et al. Risk factors for metachronous colorectal cancer following a primary colorectal cancer: A prospective cohort study[J]. Int J Cancer, 2016,139(5):1081-109010.1002/ijc.30153Suche in Google Scholar PubMed PubMed Central

[18] Shi Y, He B, Kuchenbecker KM, et al. Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells[J]. Int J Cancer, 2007,121(6):1175-118110.1002/ijc.22848Suche in Google Scholar PubMed

[19] Yamaki S, Fujii T, Yajima R, et al. Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer[J]. Surg Today, 2013,43(8):901-90510.1007/s00595-012-0378-3Suche in Google Scholar PubMed

[20] Knapp JS, Lokeshwar SD, Vogel U, et al. Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence[J]. World J Urol, 2013,31(2):351-35810.1007/s00345-012-0925-ySuche in Google Scholar PubMed

[21] Kosacka M, Piesiak P, Kowal A, et al. Galectin-3 and cyclin D1 expression in non-small cell lung cancer[J]. J Exp Clin Cancer Res, 2011,30:10110.1186/1756-9966-30-101Suche in Google Scholar PubMed PubMed Central

[22] Canesin G, Gonzalez-Peramato P, Palou J, et al. Galectin-3 expression is associated with bladder cancer progression and clinical outcome[J]. Tumour Biol, 2010,31(4):277-28510.1007/s13277-010-0033-9Suche in Google Scholar PubMed

[23] Wang SC, Zhang ZS, Xia XZ, et al. Expression of Galectin-3 and E-cadherin in gastric adenocarcinoma tissue: Relationship with angiogenesis [J]. World Chinese journal of digestology, 2015,(21):3361-336510.11569/wcjd.v23.i21.3361Suche in Google Scholar

[24] Li JY, Zhao EH, Su R, et al. Galectin-3 expression in colorectal cancer and its clinical significancer[J]. Hebei Meicine, 2014,(09):1421-1425Suche in Google Scholar

[25] Song L, Tang JW, Owusu L, et al. Galectin-3 in cancer[J]. Clin Chim Acta, 2014,431:185-19110.1016/j.cca.2014.01.019Suche in Google Scholar PubMed

[26] Newlaczyl AU, Yu LG. Galectin-3--a jack-of-all-trades in cancer[J]. Cancer Lett, 2011,313(2):123-12810.1016/j.canlet.2011.09.003Suche in Google Scholar PubMed

Received: 2016-12-5
Accepted: 2017-2-24
Published Online: 2017-7-13

© 2017 Liu Tao et al.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Artikel in diesem Heft

  1. Regular Articles
  2. Intravascular treatment of left subclavian artery aneurysm coexisting with aortic coarctation in an adult patient
  3. Regular Articles
  4. Effect of electrical stimulation on blood flow velocity and vessel size
  5. Regular Articles
  6. Live birth pregnancy outcome after first in vitro fertilization treatment in a patient with Systemic Lupus Erythematosus and isolated high positive IgA anti-β2glycoprotein I antibodies: a case report
  7. Regular Articles
  8. Periodontal ligament stem cells regulate apoptosis of neutrophils
  9. Regular Articles
  10. Platelet-rich fibrin (PRF) in implants dentistry in combination with new bone regenerative flapless technique: evolution of the technique and final results
  11. Regular Articles
  12. The significance of strong ion gap for predicting return of spontaneous circulation in patients with cardiopulmonary arrest
  13. Regular Articles
  14. Clinicopathology of EpCAM and EGFR in human epithelial ovarian carcinoma
  15. Regular Articles
  16. Intraosseous lipoma of the mandibula: A case report and review of the literature
  17. Regular Articles
  18. Transurethral resection of the prostate, bladder explosion and hyponatremic encephalopathy: a rare case report of malpractice
  19. Regular Articles
  20. Brain strokes related to aortic aneurysma – the analysis of three cases
  21. Regular Articles
  22. Effect of Bicyclol tablets on drug induced liver injuries after kidney transplantation
  23. Regular Articles
  24. Plasma free fatty acids in hyperemesis gravidarum pregnancy
  25. Regular Articles
  26. Impact of chromosomal rearrangement upon DNA methylation patterns in leukemia
  27. Regular Articles
  28. Gefitinib versus docetaxel in treated non-small-cell lung cancer: a meta-analysis
  29. Regular Articles
  30. The clinical characteristics of patients with chronic idiopathic anal pain
  31. Regular Articles
  32. Bone tunnel impaction reduced the tibial tunnel enlargement
  33. Regular Articles
  34. Effects of S-1 combined with radiotherapy in the treatment of nasopharyngeal cancer: a meta-analysis based on randomized controlled trials
  35. Regular Articles
  36. Predictions and outcomes of atrial fibrillation in the patients with acute myocardial infarction
  37. Regular Articles
  38. An accuracy study of the Intracavitary Electrocardiogram (IC-ECG) guided peripherally inserted central catheter tip placement among neonates
  39. Regular Articles
  40. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A meta-analysis
  41. Regular Articles
  42. Surface coil intensity correction in magnetic resonance imaging in spinal metastases
  43. Regular Articles
  44. Muscle stem cell and physical activity: what point is the debate at?
  45. Regular Articles
  46. MicroRNA let-7g directly targets forkhead box C2 (FOXC2) to modulate bone metastasis in breast cancer
  47. Regular Articles
  48. Monitoring health inequalities at the municipal level: Lithuanian experience
  49. Regular Articles
  50. Role of Epstein-Barr virus in the development of nasopharyngeal carcinoma
  51. Regular Articles
  52. Thrombectomy combined with indwelling-catheter thrombolysis is more effective than pure thrombectomy for the treatment of lower extremity deep venous thrombosis
  53. Regular Articles
  54. Expression of Hepcidin and Neogenin in colorectal cancer
  55. Regular Articles
  56. Carnitine and adiponectin levels in breast cancer after radiotherapy
  57. Regular Articles
  58. Pathophysiology of meningioma growth in pregnancy
  59. Regular Articles
  60. Causal neuro-immune relationships at patients with chronic pyelonephritis and cholecystitis. Correlations between parameters EEG, HRV and white blood cell count
  61. Regular Articles
  62. Measuring efficiency of secondary healthcare providers in Slovenia
  63. Regular Articles
  64. Galectin-3 expression in colorectal cancer and its correlation with clinical pathological characteristics and prognosis
  65. Regular Articles
  66. Model for studying anti- allergic drugs for allergic conjunctivitis in animals
  67. Regular Articles
  68. Barriers perceived by nurses in the optimal treatment of postoperative pain
  69. Regular Articles
  70. Tumor microenvironment in treatment of glioma
  71. Regular Articles
  72. Delirium risk of dexmedetomidine and midazolam in patients treated with postoperative mechanical ventilation: A meta-analysis
  73. Regular Articles
  74. Hemangioma of the rib: a rare case report and literature review
  75. Regular Articles
  76. The diagnostic accuracy of conventional forceps biopsy compared to ESD
  77. Regular Articles
  78. Increased miR-25 expression in serum of gastric cancer patients is correlated with CA19-9 and acts as a potential diagnostic biomarker
  79. Regular Articles
  80. Therapeutic nanomedicine surmounts the limitations of pharmacotherapy
  81. Regular Articles
  82. Relationship between PD-L1 expression and clinical characteristics in patients with breast invasive ductal carcinoma
  83. Regular Articles
  84. Trypsinogen activation peptide induces HMGB1 release from rat pancreatic acinar cells
  85. Regular Articles
  86. The effective regulation of pro- and anti-inflammatory cytokines induced by combination of PA-MSHA and BPIFB1 in initiation of innate immune responses
  87. Regular Articles
  88. Cell based therapeutic approach in vascular surgery: application and review
  89. Regular Articles
  90. Clinical efficacy of alprostadil combined with α-lipoic acid in the treatment of elderly patients with diabetic nephropathy
  91. Regular Articles
  92. Professional burnout and concurrent health complaints in neonatal nursing
  93. Regular Articles
  94. Esophageal xanthoma: presence of M2 macrophages suggests association with late inflammatory and reparative processes
  95. Regular Articles
  96. Cone beam computed tomography analysis in 3D position of maxillary denture
  97. Regular Articles
  98. CK20 mRNA expression in serum as a biomarker for colorectal cancer diagnosis: A meta-analysis
  99. Regular Articles
  100. Serum AFU, 5’-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis
  101. Regular Articles
  102. Absolute reliability and concurrent validity of hand held dynamometry and isokinetic dynamometry in the hip, knee and ankle joint: systematic review and meta-analysis
  103. Regular Articles
  104. The Fountain of Youth: A tale of parabiosis, stem cells, and rejuvenation
  105. Regular Articles
  106. Foam sclerotherapy during shunt surgery for portal hypertension and varices
  107. Regular Articles
  108. Insomnia and depression: Japanese hospital workers questionnaire survey
  109. Regular Articles
  110. Serum NF-κBp65, TLR4 as biomarker for diagnosis of preeclampsia
  111. Regular Articles
  112. Docetaxel/cisplatin therapy in myasthenia gravis with hypertension/diabetes
  113. Regular Articles
  114. Fluid resuscitation and markers of glycocalyx degradation in severe sepsis
  115. Regular Articles
  116. Modified Sauve-Kapandji procedure for patients with old fractures of the distal radius
  117. Regular Articles
  118. Bile leakage after liver transplantation
  119. Regular Articles
  120. VEGF overexpression predicts poor survival in hepatocellular carcinoma
  121. Regular Articles
  122. Galen vein aneurysm– challenge for treatment
  123. Regular Articles
  124. Retrieval of a broken sewing needle from the sacrum aided by a permanent magnet: a case report and literature review
  125. Regular Articles
  126. HIV/STI prevention interventions: A systematic review and meta-analysis
  127. Regular Articles
  128. Aortic aneurysm as a complication of myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis
  129. Regular Articles
  130. Real-time monitoring of contrast-enhanced ultrasound for radio frequency ablation
  131. Regular Articles
  132. Successful drug-eluting stent implantation in a male patient with dextrocardia: a case report
  133. Regular Articles
  134. Primary pleomorphic liposarcoma of fallopian tube with recurrence: a case report and review of the literature
  135. Regular Articles
  136. Color Doppler Ultrasound in Uterine Arterial Embolization
  137. Regular Articles
  138. Pattern of alcohol consumption by young people from North Eastern Portugal
  139. Regular Articles
  140. Effects of out-of-hospital continuing nursing on schizophrenia patients' rehabilitation and quality of life
Heruntergeladen am 22.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/med-2017-0032/html?lang=de
Button zum nach oben scrollen